

Number of citations 3830
H-index 29
Google scholar ID Angela Huttner
ORCID ID <https://orcid.org/0000-0002-8380-368X>

Publications dating from the last five years are in black font; prior publications are in grey.

■ **Original articles published in peer-reviewed journals:**

- 1- Marti C, Stirnemann J, Lescuyer P, Tonoli D, von Dach E; OPTIMAL TDM Study Group, **Huttner A**. Therapeutic drug monitoring and clinical outcomes in severely ill patients receiving amoxicillin: a single-centre prospective cohort study. *Int J Antimicrob Agents* 2022 May 6;106601. doi: 10.1016/j.ijantimicag.2022.106601
IF: 5.283
- 2- Meyer B, Martinez-Murillo PA, Lemaitre B, Blanchard-Rohner G, Didierlaurent AM, Fontannaz P, Eugercios Manzananas C, Lambert PH, Loevy N, Kaiser L, Sartoretti J, Tougne C, Villard J, **Huttner A**, Siegrist CA, Eberhardt CS. Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 - A Comprehensive Analysis. *Front Immunol.* 2022 May 2;13:841009. doi: 10.3389/fimmu.2022.841009
IF: 6.429
- 3- **Huttner A**, von Dach E, Prendki V, Harbarth S, Kaiser L. Patient and proxy recall after providing written or oral informed consent to participate in an interventional trial. *JAMA Open* 2022 May 2;5(5):e2214052. doi: 10.1001/jamanetworkopen.2022.14052
IF: 8.483
- 4- Ayada G, **Huttner A**, Avni-Nachman S, Karny-Epstein N, Matsri S, Buchrits S, Atamna A, Yahav D, Tau N. Representation of women in editorial boards of infectious disease and microbiology journals – a cross sectional study. *Clin Microbiol Infect* 2022, doi: 10.1016/j.cmi.2022.02.021
IF: 8.067
- 5- de Velde F, de Winter BCM, Neely MN, Strojil J, Yamada WM, Harbarth S, **Huttner A**, van Gelder T, Koch BCP, Muller AE, On Behalf Of The Combacte-Net Consortium. Parametric and nonparametric population pharmacokinetic models to assess probability of target attainment of imipenem concentrations in critically ill patients. *Pharmaceutics* 2021 Dec 16;13(12):2170. doi: 10.3390/pharmaceutics13122170
IF: 5.880
- 6- Vono M*, **Huttner A***, Lemeille S, Martinez-Murillo P, Meyer B, Baggio S, Sharma S, Thiriard A, Marchant A, Godeke GJ, Reusken C, Alvarez C, Perez-Rodriguez F, Eckerle I, Kaiser L, Loevy N, Eberhardt CS, Blanchard-Rohner G, Siegrist CA, Didierlaurent AM. Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity. *Cell Rep* 2021 Sep 15:109773. doi: 10.1016/j.celrep.2021.109773 (*co-first author)
IF: 9.423
- 7- Vu DL, Martinez-Murillo P, Pigny F, Vono M, Meyer B, Eberhardt CS, Lemeille S, Von Dach E, Blanchard-Rohner G, Eckerle I, **Huttner A**, Siegrist CA, Kaiser L, Didierlaurent AM. Longitudinal analysis of inflammatory response to sars-cov-2 in the upper respiratory tract reveals an association with viral load, independent of symptoms. *J Clin Immunol* 2021 Sep 28:1-10. doi: 10.1007/s10875-021-01134-z
IF: 4.227
- 8- Leo S, Lazarevic V, von Dach E, Kaiser L, Prendki V, Schrenzel J, Huttner BD, **Huttner A**. Effects of antibiotic duration on the intestinal microbiota and resistome: The PIRATE RESISTANCE project, a cohort study nested within a randomized trial. *EBioMedicine* 2021 Sep;71:103566. doi: 10.1016/j.ebiom.2021.103566
IF: 8.143
- 9- Martischang R, Godycki-Ćwirko M, Kowalczyk A, Kosiek K, Turjeman A, Babich T, Shiber S, Leibovici L, von Dach E, Harbarth S, **Huttner A**. Risk factors for treatment failure in women with uncomplicated lower urinary tract infection. *PLoS One* 2021 Aug 31;16(8):e0256464. doi: 10.1371/journal.pone.0256464
IF: 3.240
- 10- Carnino L, Vetter P, Peyraud N, Aebischer-Perone S, Chappuis F, **Huttner A**, Kaiser L, Eperon G. Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study. *J Travel Med* 2021 Jun 15:taab086. doi: 10.1093/jtm/taab086
IF: 7.089

- 11- Rossel A, Zandberg KPM, Albrich WC, **Huttner A**. How representative is a point-of-care randomized trial? Clinical outcomes of patients excluded from a point-of-care randomized controlled trial evaluating antibiotic duration for Gram-negative bacteraemia: a multicentre prospective observational cohort study. *Clin Microbiol Infect* 2021 Jun 8:S1198-743X(21)00301-3. doi: 10.1016/j.cmi.2021.05.050
IF: 8.067
- 12- L'Huillier AG, Meyer B, Andrey DO, Arm-Vernez I, Baggio S, Didierlaurent A, Eberhardt CS, Eckerle I, Grasset-Salomon C, **Huttner A**, Posfay-Barbe KM, Royo IS, Pralong JA, Vuilleumier N, Yerly S, Siegrist CA, Kaiser L; Geneva Centre for Emerging Viral Diseases. Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. *Clin Microbiol Infect* 2021 20:S1198-743X(21)00031-8
IF: 8.067
- 13- Santoro F, Donato A, Lucchesi S, Sorgi S, Gerlini A, Haks MC, Ottenhoff THM, Gonzalez-Dias P, Consortium VE, Consortium VE, Nakaya HI, **Huttner A**, Siegrist CA, Medagliani D, Pozzi G. Human transcriptomic response to the vsv-vectored ebola vaccine. *Vaccines* 2021 20;9(2):67
IF: 4.980
- 14- Turjeman A, Awwad M, Shiber S, Babich T, Eliakim-Raz N, **Huttner A**, Harbarth S, Leibovici L, Yahav D. Using external data to assess the external validity of a randomised controlled trial. *Infect Dis* 2021 53(5):325-331
IF: 3.404
- 15- **Huttner A**, Lascano AM, Roth S, Schwob JM, Eperon G, Siegrist CA, Lalive PH. Rabies vaccination and multiple sclerosis relapse: A retrospective cohort study. *Mult Scler Relat Disord* 2021 Jun;51:102906. doi: 10.1016/j.msard.2021.102906
IF: 4.339
- 16- Baggio S, L'Huillier AG, Yerly S, Bellon M, Wagner N, Rohr M, **Huttner A**, Blanchard-Rohner G, Loevy N, Kaiser L, Jacquerioz F, Eckerle I. SARS-CoV-2 viral load in the upper respiratory tract of children and adults with early acute COVID-19. *Clin Infect Dis* 2020 doi: 10.1093/cid/ciaa1157
IF: 9.079
- 17- von Dach E, Albrich W, Brunel AS, Prendki V, Cuvelier C, Flury D, Gayet-Ageron A, Huttner B, Kohler B, Lemmenmeier E, McCallin S, Rossel A, Harbarth S, Kaiser L, Bochud PY, **Huttner A**. Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial. *JAMA* 2020 323(21):2160-9
IF: 56.272
- 18- de Velde F, de Winter BCM, Neely MN, Yamada WM, Koch BCP, Harbarth S, von Dach E, van Gelder T, **Huttner A**, Mouton JW; COMBACTE-NET consortium. Population pharmacokinetics of imipenem in critically ill patients: a parametric and nonparametric model converge on CKD-EPI estimated glomerular filtration rate as an impactful covariate. *Clin Pharmacokinet* 2020 Jul;59(7):885-898. doi: 10.1007/s40262-020-00859-1
IF: 4.926
- 19- **Huttner A**, Eperon G, Lascano A, Roth S, Schwob JM, Siegrist CA, Lalive P. Risk of multiple sclerosis relapse after yellow-fever vaccine: a self-controlled case series. *Neurol Neuroimmun Neuroinflamm* 2020 May 1; 7(4)e726
IF: 7.724
- 20- Pejowski D, de Rham C, Martinez-Murillo P, Santoro F, Auderset F, Medagliani D, Pozzi G, Vono M, Lambert PH, **Huttner A**, Haks MC, Ottenhoff THM, Villard J, Siegrist CA; VEBCON Consortium; VSV-EBOVAC Consortium; VSV-EBOPLUS Consortium. Rapid dose-dependent natural killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination. *NPJ Vaccines* 2020 Apr 14;5:32. doi: 10.1038/s41541-020-0179-4
IF: 4.980
- 21- Wijma RA, **Huttner A**, van Dun S, Kloezen W, Abbott IJ, Muller AE, Koch BCP, Mouton JW. Urinary antibacterial activity of fosfomicin and nitrofurantoin at registered dosages in healthy volunteers. *Int J Antimicrob Agents* 2019 Oct;54(4):435-441
IF: 4.621
- 22- Zanichelli V, **Huttner A**, Harbarth S, Kronenberg A, Huttner B, Swiss Centre For Antibiotic Resistance Anresis. Antimicrobial resistance trends in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis urinary isolates from Switzerland: retrospective analysis of data from a national surveillance network over an 8-year period (2009-2016). *Swiss Med Wkly* 2019 Jul 24;149:w20110. doi: 10.4414/smw.2019.20110. eCollection 2019 Jul 15
IF: 1.812
- 23- **Huttner A**, Wijma R, Stewardson A, Olearo F, Von Dach E, Harbarth S, Bruggeman R, Mouton J, Muller A. The pharmacokinetics of nitrofurantoin in healthy female volunteers: a randomized cross-over study. *J Antimicrob Chemother* 2019 doi: 10.1093/jac/dkz095
IF: 5.790

- 24- Bricheux A, Lenggenhager L, Hughes S, Karmime A, Lescuyer P, **Huttner A**. Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalised patients: a retrospective cohort study. *Clin Microbiol Infect* 2018 Mar;25(3):383.e1-383.e4. doi: 10.1016/j.cmi.2018.11.020
IF: 8.067
- 25- **Huttner A**, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Ćwirko M, Mouton JW, Harbarth S. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial. *JAMA* 2018 May 1;319(17):1781-1789
IF: 56.272
- 26- **Huttner A**, Agnandji S, Combescure C, Fernandes J, Bache E, Kabwende L, N'dungu F, Brosnahan J, Monath T, Lemaître B, Grillet S, Botto M, Engler O, Portmann J, Siegrist D, the VEBCON, VSV-EBOVAC and VSV-EBOPLUS Consortia⁺, Bejon P, Silvera P, Kremsner P, Siegrist CA. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination: an observational cohort study. *Lancet Infectious Diseases* 2018 Jul;18(7):738-748
IF: 25.071
- 27- **Huttner A**, Albrich WC, Bochud PY, Gayet-Ageron A, Rossel A, Dach EV, Harbarth S, Kaiser L. PIRATE project: point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia. *BMJ Open* 2017 Jul 13;7(7):e017996
IF: 2.496
- 28- **Huttner A**, Combescure C, Grillet S, Haks MC, Quinten E, Modoux C, Agnandji ST, Brosnahan J, Dayer JA, Harandi AM, Kaiser L, Medagliani D, Monath T; VEBCON and VSV-EBOVAC Consortia, Roux-Lombard P, Kremsner PG, Ottenhoff TH, Siegrist CA. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. *Sci Transl Med* 2017 Apr 12;9(385)
IF: 17.956
- 29- Ruppé E, Olearo F, Pires D, Baud D, Renzi G, Cherkaoui A, Goldenberger D, **Huttner A**, François P, Harbarth S, Schrenzel J. Clonal or not clonal? Investigating hospital outbreaks of KPC-producing *Klebsiella pneumoniae* with whole-genome sequencing. *Clin Microbiol Infect* 2017 Jul; 23(7):470-475
IF: 8.067
- 30- **Huttner A**, Hatz C, van den Dobbelen G, Abbanat D, Hornacek A, Frölich R, Dreyer AM, Martin P, Davies T, Fae K, van de Nieuwenhof, Thoelen S, de Vallière S, Kuhn A, Bernasconi E, Viereck V, Kavvadias T, Kling K, Ryu G, Hülder T, Gröger S, Scheiner D, Alaimo C, Harbarth S, Poolman J, Fonck VG. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extra-intestinal pathogenic *Escherichia coli* (ExPEC) in women with a history of recurrent urinary tract infection: a randomized, placebo-controlled trial. *Lancet Infect Dis* 2017(5):528-537
IF: 25.071
- 31- Dayer J-A, Siegrist C-A, **Huttner A**. Volunteer feedback and perceptions after participation in a phase I, first-in-human ebola vaccine trial: an anonymous survey. *PLoS One* 2017 Mar 8;12(3):e0173148
IF: 3.240
- 32- Huwylar T, Lenggenhager L, Abbas Mo, Ing Lorenzini K, Hughes S, Huttner B, Karmime A, Uçkay I, von Dach E, Lescuyer P, Harbarth S, **Huttner A**. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. *Clin Microbiol Infect* 2017 Jul;23(7):454-459
IF: 8.067
- 33- **Huttner A**, Cacace M, d'Andrea L, Skevaki C, Otelea D, Pugliese F, Tacconelli E. Inequality dynamics in the workplace among microbiologists and infectious disease specialists: a qualitative study in five European countries. *Clin Microbiol Infect*. 2017 May;23(5):332.e1-332.e9
IF: 8.067
- 34- Muller AE, Verhaegh EM, Harbarth S, Mouton JW, **Huttner A**. Nitrofurantoin's efficacy and safety as prophylaxis for urinary tract infections: a systematic review of the literature and meta-analysis of controlled trials. *Clin Microbiol Infect* 2017 Jun;23(6):355-362
IF: 8.067
- 35- Nelson RE, Jones M, Leecaster M, Samore MH, Ray W, **Huttner A**, Huttner B, Khader K, Stevens VW, Gerding D, Schweizer ML, Rubin MA. An Economic Analysis of Strategies to Control *Clostridium Difficile* Transmission and Infection Using an Agent-Based Simulation Model. *PLoS One* 2016, Mar 31;11(3):e0152248
IF: 3.240
- 36- **Huttner A**, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a

- randomised double-blind, placebo-controlled phase I/II trial. *Lancet Infect Dis* 2015, 15(10):1156-66
IF: 25.071
- 37- **Huttner A**, Verhaegh E, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled clinical trials. *J Antimicrob Chemother* 2015, 70(9):2456-64
IF: 5.790
- 38- Selidji A**, **Huttner A****, Zinser M**, Njuguna P**, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharther M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA. Phase I Trials of rVSV Ebola Vaccine in Africa and Europe. *N Engl J Med* 2016, 374(17):1647-60 **co-first author
IF: 91.245
- 39- **Huttner A**, Von Dach E, Renzoni A, Huttner B, Affaticati M, Pagani L, Daali Y, Pugin J, Karmime A, Fathi M, Lew D, Harbarth S. Augmented renal clearance, low beta-lactam concentrations, and clinical outcomes in the critically ill: a prospective pilot study. *Inter J Antimicrob Ag* 2015, 45(4):385-92
- 40- **Huttner A**, Emonet S, Harbarth S, Renzi G, Kaiser L, Schrenzel J. Polymerase-chain reaction/electrospray ionization-mass spectrometry for the detection of bacteria and fungi in bronchoalveolar lavage fluids: a prospective observational study. *Clin Microbiol Infect* 2014, 20(12):O1059-66
- 41- Jones M, Huttner B, Leecaster M, **Huttner A**, Damal K, Tanner W, Nielson C, Rubin MA, Goetz MB, Madaras-Kelly K, Samore MH. Does universal active MRSA surveillance influence anti-MRSA antibiotic use? A retrospective analysis of the treatment of patients admitted with suspicion of infection at Veterans Affairs Medical Centers between 2005 and 2010. *J Antimicrob Chemother* 2014, 69(12):3401-8
- 42- Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, Frey O, Harbarth S, **Huttner A**, McWhinney B, Missel B, Pea F, Preisenberger J, Roberts MS, Robertson TA, Roehr A, Bruck Sime F, Taccone FS, Ungerer JPJ, Lipman J, Roberts JA. An international, multicentre survey of β -lactam antibiotic therapeutic drug monitoring practice in intensive care units. *J Antimicrob Chemother*. 2014, 69(5):1416-23
- 43- Rubin MA, Jones M, Leecaster M, Khader K, Ray W, **Huttner A**, Huttner B, Toth D, Sablay T, Borotkanics RJ, Gerding DN, Samore MH. A simulation-based assessment of strategies to control *Clostridium difficile* transmission and infection. *PLoS One* 2013, 8(11):e80671
- 44- Huttner B, Jones M, **Huttner A**, Rubin M, Samore MH. Antibiotic prescription practices for pneumonia, skin and soft tissue infections, and urinary tract infections throughout the US Veterans Affairs system. *J Antimicrob Chemother* 2013, 68(10):2393-9
- 45- Pasche E, Ruch P, Teodoro D, **Huttner A**, Harbarth S, Gobeill J, Wipfli R, Lovis C. Assisted knowledge discovery for the maintenance of clinical guidelines. *PLoS One* 2013, 8(4):e62874
- 46- Perez C*, **Huttner A***, Assal M, Bernard L, Lew D, Hoffmeyer P, Uçkay I. Infectious olecranon and patellar bursitis: short-course adjuvant antibiotic therapy is not a risk factor for recurrence in adult hospitalized patients. *J Antimicrob Chemother* 2010, 65(5): 1008-1114 *equal contribution as first author
- 47- Flammer AJ, Vo NT, Ledergerber B, Hermann F, Gämperli A, **Huttner A**, Evison J, Weber R. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomized controlled trial. *Heart* 2009, 95: 385 – 390
- 48- **Huttner A**, Kaufmann G, Battegay M, Opravil M, and the Swiss HIV Cohort Study. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy. *AIDS* 2007, 21: 939-946
- 49- Lüthi B, **Huttner A**, Speck RF, Mueller NJ. Methadone-induced torsade de pointes after stopping lopinavir-ritonavir. *Eur J Clin Microbiol Infect Dis* 2007, 10: 293 - 295

■ Review articles published in peer-reviewed journals:

- 50- Genevière J, McCallin S, **Huttner A**, Pham T, Suva D. A systematic review of phage therapy applied to bone and joint infections: an analysis of success rates, treatment modalities and safety. *EFORT Open Rev*. 2021 Dec 10;6(12):1148-1156.
IF: 2.295
- 51- Prendki V, Tau N, Avni T, Falcone M, **Huttner A**, Kaiser L, Paul M, Leibovici-Weissmann Y, Yahav D; ESCMID Study Group for Infections in the Elderly (ESGIE). A systematic review
Publication list, A. Huttner

- assessing the under-representation of elderly adults in COVID-19 trials. *BMC Geriatr* 2020;20(1):538
IF: 3.077
- 52- Tängdén T, Lundberg CV, Friberg LE, **Huttner A**. How preclinical infection models help define antibiotic doses in the clinic. *Int J Antimicrob Agents* 2020 May 7:106008
IF: 4.621
- 53- **Huttner A**, Bielicki J, Clements MN, Fridodt-Møller N, Muller AE, Paccaud JP, Mouton JW. Oral amoxicillin and amoxicillin-clavulanate: properties, indications, and usage. *Clin Microbiol Infect* 2019 Jul;26(7):871-879. doi: 10.1016/j.cmi.2019.11.028
IF: 8.067
- 54- **Huttner A**, Siegrist CA. Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know? *Exp Rev Vaccines* 2018; 17(12):1105-1110
IF: 4.222
- 55- Wijma R, **Huttner A**, Koch B, Mouton JW, Muller AE. Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline. *J Antimicrob Chemother* 2018 Nov 1;73(11):2916-2926
IF: 5.790
- 56- **Huttner A**, Gambillara Fonck V. How it was done: the development of the conjugated *Escherichia coli* vaccine from bench to clinical trials. *Clin Microbiol Infect* 2018 pii: S1198-743X(18)30440-3. doi: 10.1016/j.cmi.2018.05.009
IF 8.067
- 57- Muller A, Huttner B, **Huttner A**. Therapeutic drug monitoring of beta-lactam and other antibiotics in the intensive care unit: which agents, which patients and which infections? *Drugs* 2018 Feb 23. doi: 10.1007/s40265-018-0880-z
IF: 4.690
- 58- Abbas M, Paul M, **Huttner A**. New and improved? A review of novel antibiotics for Gram-positive bacteria. *Clin Microbiol Infect* 2017 Jun 19. pii: S1198-743X(17)30329-4.
IF: 8.067
- 59- **Huttner A**, Harbarth S, Hope W, Lipman J, Roberts J. Therapeutic drug monitoring of the beta-lactam antibiotics: what is the evidence and which patients should we be using it for? *J Antimicrob Chemother* 2015 Jul 17. pii: dkv201
IF: 5.790
- 60- **Huttner A**, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A, Jarlier V, Voss A, Pittet D for the World Healthcare-associated Infections Forum participants. Antimicrobial resistance: a global view from the 2013 World Healthcare-associated Infections Forum. *Antimicrob Resist Infect Contr* 2013, 18;2(1):31
IF: 4.510

■ Position papers published in peer-reviewed journals:

- 61- **Huttner A**, Bricheux A, Buurmeijer-van Dijk CJM, Harvey M, Holmes A, Lassmann B, Lavergne V, Mailles A, Mendelson M, Muller N, Sanguinetti M, Sears C, Skevaki C, Syed U, Thomas S, Swartz TH; European Society of Clinical Microbiology and Infectious Diseases; Federation of European Microbiological Societies; Infectious Disease Society of America; International Society for Infectious Diseases; Swiss Society for Infectious Diseases. Joint ESCMID, FEMS, IDSA, ISID and SSI position paper on the fair handling of career breaks among physicians and scientists when assessing eligibility for early-career awards. *Clin Microbiol Infect* 2021 18:S1198-743X(21)00056-2
IF: 8.067

■ Editorials and viewpoints published in peer-reviewed journals:

- 62- Leibovici L, Rodríguez-Baño J, Chemaly RF, Cutler S, **Huttner A**, Kalil AC, Leeflang M, Lina G, Paul M, Scudeller L, Tassios PT, Yusuf E. Prediction models in CMI. *Clin Microbiol Infect* 2021 Dec 10:S1198-743X(21)00701-1. doi: 10.1016/j.cmi.2021.12.004 (epub ahead of print)
IF: 8.067
- 63- Scudeller L, **Huttner A**, Paul M, Rodríguez-Baño J, Leibovici L. Abandoned trials in infection diseases and clinical microbiology: a call for action. *Clin Microbiol Infect* 2021 27(4):501-502
IF: 8.067
- 64- Cusumano JA, Klinker KP, **Huttner A**, Luther MK, Roberts JA, LaPlante KL. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β -lactam antibiotics to

- maximize effectiveness and minimize toxicity. *Am J Health Syst Pharm* 2020 Jul 7;77(14):1104-1112
IF: 1.882
- 65- Paul M, Harbarth S, **Huttner A**, Thwaites GE, Theuretzbacher U, Bonten MJM, Leibovici L. Investigator-initiated randomized controlled trials in infectious diseases: better value for money for registration trials of new antimicrobials. *Clin Infect Dis* 2020 Jul 3;ciaa930. doi: 10.1093/cid/ciaa930.
IF: 9.079
- 66- **Huttner A**, Friedman J. Author gender and editors' decisions at *Clin Microbiol Infect* 2019; 25(4):397-398
IF: 8.067
- 67- **Huttner A**. Cefiderocol in context. *Lancet Infect Dis* 2018 doi.org/10.1016/S1473-3099(18)30615-7
IF: 25.071
- 68- **Huttner A**. An ounce of prevention. *Clin Microbiol Infect* 2018 Oct;24(10):1037-1038
IF 8.067
- 69- **Huttner A**, Pulcini C. CMI and "primary-care" infections. *Clin Microbiol Infect* 2018 Aug;24(8):797-798
IF: 8.067
- 70- Pulcini C, **Huttner A**. CMI Policy on antimicrobial stewardship research. *Clin Microbiol Infect* 2018 Feb;24(2):91-92
IF: 8.067
- 71- **Huttner A**, Kaiser L and the CMI editors. Fair reporting of results. *Clin Microbiol Infect* 2017 Jun;23(6):345-346
IF: 8.067
- 72- **Huttner A**, Leibovici L, Theuretzbacher U, Huttner B, Paul M. Closing the evidence gap in infectious disease: point-of-care randomization and informed consent. *Clin Microbiol Infect* 2017 Feb;23(2):73-77
IF: 8.067
- 73- **Huttner A**, Harbarth S. Beads vs. Bugs? *Chest* 2012, 141(5): 1136-7

■ Letters published in peer-reviewed journals:

- 74- **Huttner A**. Cefiderocol in context—reply. *Lancet Infect Dis*. 2018 19(1):24-25
IF: 25.071
- 75- **Huttner A**, Leibovici L, Harbarth S. Antibiotic treatment for uncomplicated urinary tract infections—reply. *JAMA* 2018 Sep 25;320(12):1284-1285
IF: 56.272
- 76- Albrich WC, Huttner BD, **Huttner A**. Validation of IDSA/ATS Algorithm for Duration of Pneumonia Therapy. *JAMA Intern Med*. 2017 Feb 1;177(2):283-284
IF: 21.900
- 77- Slekovec C, Leroy J, **Huttner A**, Ruyer O, Talon D, Hocquet D, Bertrand X. When the precautionary principle disrupts three years of antibiotic stewardship: nitrofurantoin in the treatment of urinary tract infections. *J Antimicrob Chemother* 2014, 69(1):282-4
- 78- **Huttner A**, Calmy A. Treatment of HIV infection with drugs for HSV-2 infection. *Lancet* 2010 375(9717):782 – 784
- 79- **Huttner A**, Harbarth S. Guidelines for vancomycin use. *Clin Infect Dis* 2010 50(4): 616

■ Articles submitted to peer-reviewed journals:

- 80- Last K, Hübsch L, Cevik M, Wolkewitz M, Müller SE, **Huttner A**, Papan C. Association between woman authorship and woman editorship in infectious diseases journals: a cross-sectional study (in revision at *Lancet Infectious Diseases*)
- 81- Roth R, Lidén M, **Huttner A**. The urobiome in men and women: a clinical review. (Invited review article; in revision at *Clin Microbiol Infect*)
- 82- Marti C, Stirnemann J, Karmime A, Lescuyer P, Tonoli D, von Dach E, **Huttner A**. Therapeutic drug monitoring and clinical outcomes in critically ill patients receiving amoxicillin: a single-center prospective cohort study (in revision at *Int J Antimicrob Ag*)
- 83- Smit C, Sen S, von Dach E, Karmime A, Lescuyer P, Tonoli D, Bielicki J, **Huttner A**, Pfister M. Current dose reductions for amoxicillin in hospitalized patients with impaired kidney function lead to subtherapeutic concentrations (under review at *Clin Microbiol Infect*)

■ Articles published in non-peer-reviewed journals:

- 84- Nguyen A, Posfay-Barbe K, Blanchard-Rohner G, Buvelot H, Eberhardt C, Huttner B, Negro F, Pham TT, Schibler M, Vetter P, Wagner N, Zanella MC, Jacquéroz F, **Huttner A**. Maladies infectieuses. *Rev Med Suisse* 2021 13;17(720-1):42-49
- 85- Zanella MC, Schoofs F, Huttner B, **Huttner A**. Lower urinary tract infections in men: urethritis, cystitis, and prostatitis. *Rev Med Suisse* 2017; 13(558):808-814.
- 86- Kaiser L, Emonet S, **Huttner A**, Vetter P, Toutous Trelu L, Uriel Valladares Bickel P, Lecompte T. Infectious diseases update: 2014 is viral. *Rev Med Suisse*. 2015 Jan 14;11(456-457):72-7.
- 87- Hasse B, **Huttner A**, Huttner B, Egger M, Zanetti G, Marschall J, Mühlemann K, Harbarth S. Swiss guidelines on the treatment of uncomplicated urinary tract infections. Swiss Society for Infectious Diseases 2014, <http://www.sginf.ch/guidelines/guidelines-of-the-ssi.html>

■ Book chapters:

- 88- Ansaldi Y, Nguyen A, **Huttner A**, Martinez de Tejada Weber B. Urinary infections in pregnancy. In: *The Global Library of Women's Medicine: Continuous Textbook of Women's Medicine*, Foundation for the Global Library of Women's Medicine, 2021.
- 89- **Huttner A**, Stewardson A. Nitrofurans: nitrofurazone, furazolidone and nitrofurantoin. In Kucer's *The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic and Antiviral Drugs*, 7th ed. Edward Arnold, Ltd. 2016
- 90- **Huttner A**, Harbarth S. Miscellaneous agents: fusidic acid, nitrofurantoin, and fosfomycin. In: *Infectious Diseases*, 4th ed. Cohen & Powderly, Mosby 2015

■ Thesis:

Huttner A. *L'épidémie de la maladie du virus Ebola et le vaccin VSV-EBOV : un essai clinique de phase I dans une situation d'urgence*. University of Geneva, Faculty of Medicine, 12 October 2016. (<http://archive-ouverte.unige.ch>)

■ Abstracts presented at international congresses:

Huttner A, von Dach E, Prendki V, Harbarth S, Kaiser L. Patient and proxy recall after providing written or oral informed consent to participate in an interventional trial. 32nd ECCMID (European Congress of Clinical Microbiology and Infectious Diseases), Lisbon, Portugal, 23-26 April 2022 (ESCMID)

Marti C, Stirnemann J, Karmime A, Lescuyer P, Tonoli D, von Dach E, **Huttner A**. Therapeutic drug monitoring and clinical outcomes in critically ill patients receiving amoxicillin: a single-center prospective cohort study. 32nd ECCMID (European Congress of Clinical Microbiology and Infectious Diseases), Lisbon, Portugal, 23-26 April 2022 (ESCMID)

Sen S, Smit C, von Dach E, Karmime A, Lescuyer P, Tonoli D, Bielicki J, Pfister M, **Huttner A**. Should we reduce the amoxicillin dose in patients with an impaired renal function? Dose exploration using population pharmacokinetic analysis in hospitalized patients with varying renal function, age and disease severity. 31st ECCMID (European Congress of Clinical Microbiology and Infectious Diseases), virtual, July 10-13, 2021 (ESCMID)

Leo S, Lazarevic V, von Dach E, Kaiser L, Prendki V, Schrenzel J, Huttner BD, **Huttner A**. Effects of antibiotic duration on the intestinal microbiota and resistome: the PIRATE RESISTANCE project, a cohort study nested within a randomized trial. 31st ECCMID (European Congress of Clinical Microbiology and Infectious Diseases), virtual, July 10-13, 2021 (ESCMID)

Von Dach E, Albrich W, Brunel AS, Prendki V, McCallin S, Cuvelier C, Flury D, Gayet-Ageron A, Kohler P, Lemmenmeier E, Harbarth S, Kaiser L, Bochud P, **Huttner A**. "Clinical Effectiveness of C-Reactive-Protein-Guided Durations and Fixed, Seven-Day Durations of Antibiotic Therapy Compared to 14-Day Durations for Gram-Negative Bacteremia: A Randomized Clinical Trial." 30th ECCMID

(European Congress of Clinical Microbiology and Infectious Diseases), Paris, France, April 23-26, 2020 (ESCMID)

Prendki V, Von Dach E, Albrich W, Brunel AS, Cuvelier C, Flury D, Gayet-Ageron A, Huttner B, Kohler P, Lemmenmeier E, Harbarth S, Kaiser L, Bochud P, **Huttner A**. “C-reactive protein patterns by age, sex and pathogen in patients with gram-negative bacteremia.” 30th ECCMID, Paris, France, April 23-26, 2020

Von Dach E, Prendki V, Brunel AS, Guillet A, Guyaz-Jaques C, Flury D, Kessler S, Kohler P, Knapp C, Lemmenmeier E, Albrich W, Bochud PY, Harbarth S, Kaiser L, **Huttner A**. “The PIRATE Project: pathogens and resistance profiles in patients with gram-negative bloodstream infections.” 29th ECCMID, Amsterdam, Netherlands, April 13-16, 2019

Bricheux A, Mailles A, Sanguinetti M, Skevaki C, **Huttner A**. “Career breaks in medicine and early-career awards: missing the bus?” 29th ECCMID, Amsterdam, Netherlands, April 13-16, 2019

Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-ćwirko M, Mouton JW, Harbarth S. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial. 28th ECCMID (late breaker clinical trials session), Madrid, Spain, April 21-24, 2018

Bricheux A, Abbas M, Karmime A, Lenggenhager L, Lescuyer P, Pugin J, **Huttner A**. Low toxicity, low plasma concentrations and relatively high clinical failure in patients undergoing imipenem therapeutic drug monitoring (TDM). 28th ECCMID, Madrid, Spain, April 21-24, 2018

Huttner A, Brossier C, von Dach E, Kowalczyk A, Godycki-ćwirko M, Babich T, Turjeman A, Leibovici L, Theuretzbacher U, Mouton J, Harbarth S. Increasing nitrofurantoin resistance in *Escherichia coli* urinary isolates in a country with over-the-counter antibiotic sales. 27th ECCMID, Vienna, Austria, April 22-25, 2017

Lenggenhager L, Abbas M, Fankhauser C, Huttner B, Harbarth S, **Huttner A**. Emergence of *Pseudomonas aeruginosa* resistance in patients with imipenem therapeutic drug monitoring. 27th ECCMID, Vienna, Austria, April 22-25, 2017

Huttner A, Harbarth S, Hatz C, Fae K, Davies T, van den Dobbelen G, Hornacek A, Dreyer A, Martin P, Alaimo C, Gambillara Fonck V. Candidate vaccine against extra-intestinal pathogenic *E. coli*: a multicenter phase I, first-in-human, randomized, placebo-controlled trial in women with a history of recurrent urinary tract infection. ASM Microbe & ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy), Boston, MA (USA), June 18-22, 2016 (American Society of Microbiology)


Huttner A, Von Dach E, Renzoni A, Huttner B, Affaticati M, Pagani L, Daali Y, Pugin J, Karmime A, Fathi M, Harbarth S. Augmented Renal Clearance, Subtherapeutic Beta-lactam Concentrations, and Clinical Outcomes in the Critically Ill. 53rd ICAAC Scientific Meeting, Denver, CO, Sept. 10 – 13, 2013

Huttner A, Von Dach E, Liassine N, Descombes MC, Auckenthaler R, Renzi G, François P, Harbarth S, Sudre P for the Cantonal Antibiotic Resistance Group of Geneva. Surveillance and Control of Community-associated Methicillin-resistant *Staphylococcus aureus* in Geneva, Switzerland, 2002 – 2012. 2nd ICPC Scientific Meeting, Geneva, Switzerland, June 25 – 28, 2013

Huttner A, Huttner B, Jones M, Rubin M, Nielson C, Mayer J, Samore M. “Antibiotic Use in Veterans Affairs Long-term-care Facilities: a Nationwide Analysis Using Barcode Medication Administration Data, 2007 – 2009.” IDWeek Scientific Meeting, San Diego, CA, Oct 17 – 21, 2012, Abstract 724

Jones M, Huttner B, **Huttner A**, Nielson C, Samore M, Rubin M. “Can Active Methicillin-Resistant *Staphylococcus aureus* Surveillance Increase Vancomycin Use? A Retrospective Analysis of Antibiotic Use and Microbiology Data from 129 Veterans Affairs Hospitals between 2005 and 2010.” IDWeek Scientific Meeting, San Diego, CA, Oct 17 – 21, 2012, Abstract 753

■ Signature:



Geneva, 21 April 2022